Cancer constitutes a major global health concern. Surgery, chemotherapy, and radiation therapy are prevalent treatments; yet, they frequently prove ineffective due to their systemic toxicity, the ineffectiveness of pharmacological agents, and their invasive nature. These challenges necessitate the investigation of innovative therapeutic strategies that specifically target cancer cells while reducing damage to normal tissues. Natural phytocompounds with pro-oxidant characteristics have gathered interest as potential anticancer agents. Cancer cells, which have high metabolic activity and damaged mitochondria, are always under oxidative stress. This alteration in redox homeostasis makes it more likely that they will have even more reactive oxygen species (ROS) in their systems. Pro-oxidant phytocompounds damage mitochondria, disrupt energy metabolism, and activate apoptotic pathways very selectively by pushing ROS levels past the cellular threshold. This kills the cancer cells while leaving healthy cells unharmed. New evidence has shown that a vast array of plant-based compounds, including polyphenols, terpenes, and alkaloids, have been identified to act as pro-oxidants by altering the mitochondrial membrane potential, inhibiting antioxidant defense systems, and disrupting redox-sensitive signaling pathways. However, obstacles persist in enhancing their specificity, bioavailability, and delivery systems. This review discusses the therapeutic potential of natural pro-oxidant phytocompounds in targeting mitochondrial vulnerabilities of cancer cells and bottlenecks that must be addressed for successful clinical translation. Harnessing these agents may pave the way for safer and more effective cancer treatments that exploit the intrinsic weaknesses of tumor bioenergetics.
Dimri et al. (Thu,) studied this question.